Trial Profile

A Phase 1, Multiple Ascending Dose Study Analyzing Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jun 2024 Results assessing safety and MASLD-relevant pharmacodynamic of GL0034 presented in the Sun Pharmaceutical Industries Media Release.
22 Jun 2024 According to a Sun Pharmaceutical Industries media release, the results form this trial were presented at the 84th Scientific Sessions of the American Diabetes Association (ADA), on June 21, 2024.
06 Oct 2023 Results assessing safety and tolerability of single-ascending doses of utreglutide presented at the 59th Annual Meeting of the European Association for the Study of Diabetes

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com